The E.MPD, Evotec‘s Molecular Patient Database, is becoming more and more a key component of the daily research and drug discovery efforts at Evotec.   E.MPD is a growing patient database in collaboration with high quality patient cohorts that will re-define patient populations according to disease mechanisms and understanding of the continuum from healthy to disease rather than symptoms, which is THE entry point for precision medicine.

Our multi-omics platform, PanOmics, as well as Evotec’s proprietary software solution, PanHunter, are essential components that are required for the generation of this very unique molecular patient database. 

In addition to the OMICS data that Evotec is generating on patient samples, very rich clinical records of 50 to 500 different categories contribute to stratification of patients and proper understanding of the OMICS data.  

Combining high-quality clinical data with multi-omics data in E.MPD generates the following value chains:  

• The development of 1st in class therapies 
• Biomarker discovery and clinical trial support  
• Next generation patient stratification / diagnostics (EVOgnostic) 

Altogether, this deep understanding of human diseases is going to significantly improve the Probability of Success for all programs of Evotec’s drug discovery & development pipeline. 

Out of more than 30 different diseases we have filtered a number of highly valuable targets and progressed those towards target validation and drug discovery already.